Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL

COLLEGIUM PHARMACEUTICAL

COLLEGIUM PHARMACEUTICAL, INC

COLLEGIUM PHARMACEUTICAL drug portfolio — 48 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
Status
Public
HQ
100 Technology Center Dr, Stoughton, Massachusetts 02072, US
Employees
617
Programs
29
Drugs
48
Patents
28
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Drug Pipeline

COLLEGIUM PHARMACEUTICAL pipeline

Portfolio lens on 48 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

COLLEGIUM PHARMACEUTICAL drug portfolio — 48 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

48 compounds

  1. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  2. administration

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  4. apomorphine hydrochloride

    US regulatory status: approved. Molecular target: D2-like dopamine receptor.

    Target
    D2-like dopamine receptor
    Mechanism
    D2-like dopamine receptor agonist

  5. aspirin

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  6. capsule

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  7. capsules

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  8. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  9. carmellose sodium

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records. Mechanism: Unknown.

    Mechanism
    Unknown

  10. chloride

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  13. dinutuximab beta

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in COLLEGIUM PHARMACEUTICAL's portfolio. Molecular target: Disialoganglioside GD2.

    Target
    Disialoganglioside GD2
    Mechanism
    Disialoganglioside GD2 inhibitor

  14. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  15. escalation

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  16. etirinotecan pegol

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in COLLEGIUM PHARMACEUTICAL's portfolio. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  17. evolocumab

    Cardiovascular system (C10)

    US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.

    Target
    Proprotein convertase subtilisin/kexin type 9
    Mechanism
    Subtilisin/kexin type 9 inhibitor

  18. ezetimibe

    US regulatory status: approved. Molecular target: NPC1-like intracellular cholesterol transporter 1.

    Target
    NPC1-like intracellular cholesterol transporter 1
    Mechanism
    Niemann-Pick C1-like protein 1 inhibitor

  19. glycerol

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  20. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  21. infusion

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  22. iodine

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  23. irinotecan

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  24. ivabradine

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4.

    Target
    Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
    Mechanism
    Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker

  25. magnesium

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  26. methoxyflurane

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive modulator

  27. methylphenidate

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Norepinephrine transporter inhibitor

  28. methylphenidate hydrochloride

    Nervous system (N06)

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Dopamine transporter inhibitor

  29. monohydrate

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  30. morphine

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  31. oxycodone

    US regulatory status: approved. Molecular target: Mu-type opioid receptor.

    Target
    Mu-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  32. pioglitazone

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in COLLEGIUM PHARMACEUTICAL's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.

    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  33. pioglitazone hydrochloride

    US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.

    Target
    Peroxisome proliferator-activated receptor gamma
    Mechanism
    Peroxisome proliferator-activated receptor gamma agonist

  34. placebo

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  35. progression

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  36. rifaximin

    US regulatory status: approved. Molecular target: Bacterial DNA-directed RNA polymerase.

    Target
    Bacterial DNA-directed RNA polymerase
    Mechanism
    Bacterial DNA-directed RNA polymerase inhibitor

  37. rosuvastatin

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  38. sars-cov-

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  39. solution

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  40. starch

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  41. statin

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  42. t-cell

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  43. tablet

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  44. tablets

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  45. tapentadol hydrochloride

    US regulatory status: approved. Molecular target: Mu-type opioid receptor.

    Target
    Mu-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  46. therapy

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

  47. ticagrelor

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: P2Y purinoceptor 12.

    Target
    P2Y purinoceptor 12
    Mechanism
    Purinergic receptor P2Y12 negative allosteric modulator

  48. treatment

    Development asset linked to COLLEGIUM PHARMACEUTICAL in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.